-
Plenary Session I: Thursday, October 31, 2019
"Emerging Technologies for CFTR Restoration in All People With CF"
Speaker: Marie Egan, M.D.
Genetic therapies, including RNA
therapies, gene therapies, and gene editing, hold the key to a cure for cystic
fibrosis and are moving toward the clinical realm at an unexpected pace. Moving
from the promise of these technologies to the reality of effective therapies
for the underlying cause of the disease for all people with CF and a cure for
CF will require time, tenacity, and vision.
Marie Egan, MD, from the Yale
School of Medicine, reviews the power of genetic therapies, outlines the
obstacles and challenges that lie ahead, and discusses what success looks like
as we move toward therapies that address the underlying defect for all people
with CF and a cure for cystic fibrosis.
-
Plenary Session II: Friday, November 1, 2019
"Entering the Era of Highly Effective Modulator Therapy"
Speaker: Jane C. Davies, M.D.
In this session, Professor Jane Davies from the National Heart & Lung Institute, Imperial College in London, describes the progress and the promise of highly effective CFTR modulator therapy for people with CF. She highlights the long-term benefits such therapies have had on the relatively small proportion of the CF community for whom a highly effective modulator has been available for several years -- those with the gating mutation G551D who are on ivacaftor -- and uses this evidence to describe the impact we might expect from a triple-combination drug in a larger population. The additional opportunities posed by introducing CFTR functional restoration in early life is illustrated with pre-school and infant data.
-
Plenary Session III: Saturday, November 2, 2019
"Evolution of CF Care: Innovation & Impact"
Speaker: Peter Mogayzel, M.D., Ph.D.
In this session, Dr. Peter Mogayzel walks us through past challenges and how our care model has met those challenges and built upon what we've learned to prepare for the future. As we enter a new era of therapeutics, now is the moment to consider what should shape how CF care evolves to meet the changing needs of people with CF and their families.
Following his presentation, Sue Sullivan, RN, from Oregon Health & Science University; Terri Laguna, MD, MSCS, from Ann and Robert H. Lurie Children's Hospital of Chicago; and Cindy Brown, MD, of Indiana University, join Dr. Mogayzel for a panel discussion about the factors that should influence how CF clinical care evolves to support the needs of everyone with CF.
-
Plenary Session I: Thursday, October 18, 2018
"Improving Outcomes of Infections in the Age of CFTR Modulators"
Speaker: Lisa Saiman, M.D., M.P.H.
In this session, Dr. Lisa Saiman will address the challenges
of infections in people with CF and discuss why infections remain a major focus
of the CF community, even in the era of effective CFTR modulators. She will
provide an overview of CF infections, describe ongoing studies to increase our
understanding of CF microorganisms and their optimal treatment, and discuss
current strategies to develop new anti-infective agents to treat even the most
difficult infections.
-
Plenary Session II: Friday, October 19, 2018
"Anti-inflammatories & Mucociliary Clearance Therapies in the Age of CFTR Modulators"
Speaker: Felix Ratjen, M.D., Ph.D.
This plenary will review the effect of CFTR dysfunction and
CFTR restoration on both inflammation and mucociliary clearance in individuals
with CF. Current and future therapeutic strategies to address inflammation and
mucociliary clearance will be discussed, as well as how these strategies have
potential to benefit both those patients using CFTR modulators and those not
eligible for modulators.
-
Plenary Session III: Saturday, October 20, 2018
"Partnering: The Oldest New Idea to Improve CF Care"
Speakers:
Maren Batalden, M.D., Kathryn Sabadosa, M.P.H., Melanie Abdelnour, Cynthia
George, R.N., M.S.N., F.N.P.
Central
to the management of cystic fibrosis are the relationships that people with CF
and their families build with their clinical care teams. As people with CF live
longer, their disease increases in complexity, making coordination and
individualized care ever more dependent upon these foundational relationships.
Actively partnering in health care is a learning process and although, highly
regarded, realizing and maintaining full partnership can be challenging. This
plenary will walk through the evolution of partnering, specifically in CF care
and more broadly in the context of health care and society, further thinking by
exploring the tensions impacting partnership, and highlight new strategies
supported by the CF Foundation, so that all people living with CF can better
balance their daily care while attaining personal goals. The plenary will end with
a panel discussion between an adult living with CF, a parent, and a healthcare
professional from the CF Foundation.